Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis.
Parody R, Sánchez-Ortega I, Ferrá C, Guardia R, Talarn C, Encuentra M, Fort E, López D, Morgades M, Alonso E, Ortega S, Sarrá J, Gallardo D, Ribera JM, Sureda A. Parody R, et al. Among authors: talarn c. Oncol Ther. 2020 Dec;8(2):311-324. doi: 10.1007/s40487-020-00115-3. Epub 2020 May 14. Oncol Ther. 2020. PMID: 32700041 Free PMC article.
Risk factors and outcome of COVID-19 in patients with hematological malignancies.
Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, Gómez-Catalan I, Coll R, De La Fuente I, Luna A, Merchán B, Chinea A, de Miguel D, Serrano A, Pérez C, Diaz C, Lopez JL, Saez AJ, Bailen R, Zudaire T, Martínez D, Jurado M, Calbacho M, Vázquez L, Garcia-Cadenas I, Fox L, Pimentel AI, Bautista G, Nieto A, Fernandez P, Vallejo JC, Solano C, Valero M, Espigado I, Saldaña R, Sisinni L, Ribera JM, Jimenez MJ, Trabazo M, Gonzalez-Vicent M, Fernández N, Talarn C, Montoya MC, Cedillo A, Sureda A; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Piñana JL, et al. Among authors: talarn c. Exp Hematol Oncol. 2020 Aug 25;9:21. doi: 10.1186/s40164-020-00177-z. eCollection 2020. Exp Hematol Oncol. 2020. PMID: 32864192 Free PMC article.
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.
Parody R, Sánchez-Ortega I, Mussetti A, Patiño B, Arnan M, Pomares H, González-Barca E, Mercadal S, Boqué C, Maluquer C, Carro I, Peña M, Clapés V, Verdesoto S, Bustamante G, Oliveira AC, Baca C, Cabezudo E, Talarn C, Escoda L, Ortega S, García N, Isabel González-Medina M, Sánchez-Salmerón M, Fusté C, Villa J, Carreras E, Domingo-Domènech E, Sureda A. Parody R, et al. Among authors: talarn c. Bone Marrow Transplant. 2022 Feb;57(2):176-182. doi: 10.1038/s41409-021-01506-4. Epub 2021 Oct 28. Bone Marrow Transplant. 2022. PMID: 34711917
Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation.
Fernandez-Sojo J, Cid J, Azqueta C, Valdivia E, Martorell L, Codinach M, Marsal J, Mussetti A, Esquirol A, Trabazo M, Benitez MI, Ferra C, Fox ML, Linares M, Alonso E, García-Rey E, García-Muñoz N, Medina L, Castillo-Flores N, Vall-Llovera F, Garcia A, Pinacho A, Talarn C, Arroba JG, Coll R, Santos M, Valero O, Carreras E, Lozano M, Querol S. Fernandez-Sojo J, et al. Among authors: talarn c. Bone Marrow Transplant. 2022 Aug;57(8):1341-1343. doi: 10.1038/s41409-022-01722-6. Epub 2022 May 25. Bone Marrow Transplant. 2022. PMID: 35614316 No abstract available.
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D; “Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias” (CETLAM group). Díaz-Santa J, et al. Among authors: talarn c. Eur J Haematol. 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. Epub 2022 Sep 16. Eur J Haematol. 2022. PMID: 36063368
Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
Guillem V, Calabuig M, Brunet S, Esteve J, Escoda L, Gallardo D, Ribera JM, Queipo de Llano MP, Arnan M, Pedro C, Amigo ML, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Sampol A, Salamero O, Font L, Talarn C, Hoyos M, Díaz-Beyá M, Garrido A, Navarro B, Nomdédeu J, Sierra J, Tormo M. Guillem V, et al. Among authors: talarn c. Leuk Lymphoma. 2018 Oct;59(10):2383-2393. doi: 10.1080/10428194.2017.1422858. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345176
Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment.
Gaya A, Urbano-Ispizua A, Fernández-Avilés F, Salamero O, Roncero JM, Rovira M, Martínez C, Talarn C, Granell M, Carreras E, Montserrat E. Gaya A, et al. Among authors: talarn c. Biol Blood Marrow Transplant. 2008 Aug;14(8):880-7. doi: 10.1016/j.bbmt.2008.05.008. Biol Blood Marrow Transplant. 2008. PMID: 18640571 Free article. Clinical Trial.
Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases.
Fernández-Avilés F, Urbano-Ispizua A, Aymerich M, Rovira M, Martínez C, Talarn C, Jiménez M, Carreras E, Montserrat E. Fernández-Avilés F, et al. Among authors: talarn c. Exp Hematol. 2003 Oct;31(10):934-40. doi: 10.1016/s0301-472x(03)00236-4. Exp Hematol. 2003. PMID: 14550809
Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood.
Fernández-Avilés F, Urbano-Ispizua A, Aymerich M, Colomer D, Rovira M, Martínez C, Nadal E, Talarn C, Carreras E, Montserrat E. Fernández-Avilés F, et al. Among authors: talarn c. Leukemia. 2003 Mar;17(3):613-20. doi: 10.1038/sj.leu.2402854. Leukemia. 2003. PMID: 12646952
18 results